Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Albireo Pharma Inc (ALBO) USD0.01

Sell:$30.75 Buy:$30.83 Change: $0.02 (0.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.02 (0.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.02 (0.07%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

Contact details

10 Post Office Square, Suite 502 South
United States
+1 (857) 4154774

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$592.89 million
Shares in issue:
19.26 million
United States
US dollar

Key personnel

  • David Chiswell
    Independent Chairman of the Board
  • Ronald Cooper
    President, Chief Executive Officer, Director
  • Simon Harford
    Chief Financial Officer, Treasurer
  • Michelle Graham
    Chief Human Resource Officer
  • Jan Mattsson
    Chief Scientific Officer
  • Jason Duncan
    Chief Legal Officer, General Counsel, Secretary
  • Martha Carter
    Chief Regulatory Officer
  • Patrick Horn
    Chief Medical Officer
  • Pamela Stephenson
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.